I-Mab Biopharma, a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases, and WuXi Biologics have entered into a long term strategic partnership on biologics process development, clinical and commercial manufacturing of I-Mab’s pipelines.
 
Under the terms of the partnership, I-Mab will leverage WuXi Bio’s know-how for CMC development of at least five programs and commercial manufacturing of at least one program for its proprietary monoclonal antibody, bispecific antibody and fusion protein pipelines, representing a significant expansion from the current projects that the two companies are already collaborating on.
 
“The partnership with WuXi Biologics enables our proprietary assets to move ahead more rapidly, as we are continuously and simultaneously advancing our pipeline in China and abroad, and have achieved significant development milestones,” said Zheru Zhang, president of I-Mab. “By integrating our CMC experience and product know-how with WuXi Bio’s advanced technology and capabilities, we will be able to expedite our potential first-in-class and best-in-class biologics to the market to satisfy substantial unmet medical needs with high quality and speed.”
 
Chris Chen, chief executive officer, WuXi Biologics, said, “We are excited to expand our three-year partnership to further enable I-Mab to expedite its extensive biologics pipelines across WuXi Biologics’ unparalleled capacity and world-class capabilities. This partnership further demonstrates powerful impact to our partners by combining our business strategy of ‘Follow-the-Molecule’ with our unique paradigm of ‘Global Dual Sourcing within WuXi Bio.’ We will continue to expand our robust and premier-quality global supply network in China, EU and the U.S. to enable partners and bring more biologics to patients worldwide.”